Amphastar Pharmaceuticals, Inc.
$1.32B- Market cap
- $986.03M
- Debt
- +$619.71M
- Cash
- −$282.81M
Capital structure 61% equity / 39% debt · EV / Revenue 1.84x · EV / EBITDA 6.20x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2024 ·
Decision snapshot: AMPH stock price vs CMA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CMA's multiple
Needs CMA P/E.
Implied fair value · at AMPH's multiple
Needs AMPH P/E.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMPH FY 2025 (ended Dec 31, 2025) · CMA FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 61% equity / 39% debt · EV / Revenue 1.84x · EV / EBITDA 6.20x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Amphastar Pharmaceuticals, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
COMERICA INC · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.79x
1.02x
Net debt / EBITDA
Leverage against operating earnings
1.58x
—
Cash and equivalents
Liquid reserves on the balance sheet
$282.81M
—
Total debt
Interest-bearing obligations outstanding
$619.71M
$6.67B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.